{
    "clinical_study": {
        "@rank": "48426", 
        "arm_group": {
            "arm_group_label": "Different injection speed and volume combinations", 
            "arm_group_type": "No Intervention"
        }, 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to assess and describe the pain\n      in relation to subcutaneous (under the skin) injection of different combinations of\n      injection speed and volume with respect to acceptance of the injection pain and back flow."
        }, 
        "brief_title": "Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1", 
            "Diabetes Mellitus, Type 2", 
            "Delivery Systems"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained before any trial-related activities.\n\n          -  Type 1 or type 2 diabetes\n\n          -  Daily injection(s) with anti-diabetic drug (insulin or Glucagon like Peptide-1\n             (GLP-1) analogues) via pen-injector or vial/syringe for more than 6 months\n\n          -  Body mass index (BMI) between 18.5 and 30.0 kg/m^2 (both included)\n\n          -  Caucasians\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to needle, ink ball pen or other that are in\n             contact with the injection area during the clinical visit\n\n          -  Previous participation in this trial. Participation is defined as: screened\n\n          -  Receipt of any investigational medicinal product that can influence pain perception\n             within 14 days before screening\n\n          -  Injection of more than 40 units of insulin per injection\n\n          -  Continuous Subcutaneous Insulin Infusion use within the last 6 months\n\n          -  Continuous Glucose Monitoring use within the last 6 months\n\n          -  Intake of any pain-relieving or analgesic within the last week (excluding low dose\n             aspirin in cardio vascular prophylactic doses)\n\n          -  Known active or in-active skin disease in the injection area or that may affect pain\n             perception\n\n          -  Anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular\n             prophylactic doses is allowed. However, not on the day of the injections)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01680328", 
            "org_study_id": "INS-4011", 
            "secondary_id": "U1111-1129-4191"
        }, 
        "intervention": {
            "arm_group_label": "Different injection speed and volume combinations", 
            "description": "Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of these 19 injections two are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).", 
            "intervention_name": "No treatment given", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 14, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations", 
        "overall_official": [
            {
                "affiliation": "Novo Nordisk A/S", 
                "last_name": "Berit Gors\u00f8e Kjeldsen", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Novo Nordisk A/S", 
                "last_name": "Marianne Qvist", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Institutional Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Injection pain rated on a Visual Analogue Scale (VAS) in millimetres (mm)", 
            "safety_issue": "No", 
            "time_frame": "1 minute (\u00b130 sec) after the injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01680328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Acceptance of pain for each injection (including the needle insertions only) as a binary measure (yes/no)", 
                "safety_issue": "No", 
                "time_frame": "Measured 1 minute (\u00b130 seconds) after the injections"
            }, 
            {
                "measure": "Back flow at the injection site measured as absorbed amount of liquid with filter-paper", 
                "safety_issue": "No", 
                "time_frame": "Two minutes (\u00b130 sec) after the injection rated according to a liquid scale"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}